糠酸氟替卡松/乌美溴铵/维兰特罗三联疗法与传统ICS/LAMA疗法对ACO患者的临床疗效差异分析  

Comparative analysis of clinical efficacy between fluticasone furoate/umeclidinium/vilanterol triple therapy and traditional ICS/LAMA therapy in patients with asthma-COPD overlap

作　　者：张勇[1] 党垚 陈萍[2] 刘元明[1] ZHANG Yong;DANG Yao;CHEN Ping;LIU Yuan-ming(Department of Respiratory and Critical Care Medicine,Pengzhou People′s Hospital,Pengzhou 611930,Sichuan,China;不详)

机构地区：[1]彭州市人民医院呼吸与危重症医学科,四川彭州611930 [2]彭州市人民医院耳鼻喉科,四川彭州611930

出　　处：《广东医学》2024年第6期751-756,共6页Guangdong Medical Journal

基　　金：四川青年创新科研课题计划项目(Q20031)。

摘　　要：目的探讨糠酸氟替卡松/乌美溴铵/维兰特罗(FF/UMEC/VI)三联疗法对哮喘-慢性阻塞性肺疾病重叠综合征(ACO)患者的临床疗效及与吸入型糖皮质激素(ICS)/长效抗胆碱能拮抗剂(LAMA)联合疗法的差异性。方法纳入2019年6月至2022年6月呼吸与危重症医学科收治的90例ACO患者,随机分为研究组与对照组,各45例。对照组患者予以ICS/LAMA治疗,研究组患者予以FF/UMEC/VI三联疗法治疗,治疗12周后比较两组患者用药前后肺功能指标变化、症状改善情况及疗效评价。结果治疗前研究组与对照组患者基础临床资料及各项肺功能指标差异无统计学意义(P>0.05)。治疗12周后研究组患者各项肺功能指标及血气分析指标较治疗前均显著改善(P<0.05)。不同方案治疗12周后,研究组患者各项肺功能改善程度均高于对照组患者(P<0.05)。治疗12周后研究组患者症状改善指标及治疗有效率均高于对照组患者(P<0.05)。结论FF/UMEC/VI三联疗法对于ACO患者具有显著治疗效果,能够改善患者肺功能,缓解患者临床症状,具有较为广阔的应用前景。Objective To evaluate the clinical efficacy of fluticasone furoate/umeclidinium/vilanterol(FF/UMEC/VI)triple therapy in patients with asthma-chronic obstructive pulmonary disease(COPD)overlap(ACO)and its differences compared to the traditional inhaled corticosteroid(ICS)/long-acting muscarinic antagonist(LAMA)combination therapy.Methods Ninety ACO patients admitted to the Department of Respiratory and Critical Care Medicine from June 2019 to June 2022 were randomly divided into a study group and a control group,with 45 patients in each group.The control group received ICS/LAMA treatment,while the study group received FF/UMEC/VI triple therapy.After 12 weeks of treatment,changes in lung function indicators,symptom improvement,and treatment efficacy were compared between the two groups.Results Before treatment,there were no significant differences in baseline clinical data and various lung function indicators between the study group and the control group(P>0.05).After 12 weeks of treatment,the study group showed significant improvements in various lung function and blood gas analysis indicators compared to before treatment(P<0.05).Different treatment regimens revealed that the study group had a higher degree of improvement in various lung function parameters than the control group(P<0.05)after 12 weeks of treatment.Symptom improvement indicators and treatment effectiveness were also higher in the study group than in the control group after 12 weeks of treatment(P<0.05).Conclusion FF/UMEC/VI triple therapy demonstrates significant therapeutic effects in ACO patients,improving lung function and relieving clinical symptoms.This therapy holds promising prospects for broader clinical applications.

关 键 词：哮喘-慢性阻塞性肺疾病重叠综合征 糠酸氟替卡松 乌美溴铵 维兰特罗 

分 类 号：R256.12[医药卫生—中医内科学] R563[医药卫生—中医学]